Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update

Feb 28,2019

Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and year-end 2018 financial results conference call and webcast, for Thursday, March 7, 2019.  The schedule for the press release and conference call/webcast are as follows:

Q4 2018 Press Release: March 7, 2019 at 4:00 p.m. ET
Q4 2018 Conference Call: March 7, 2019 at 4:30 p.m. ET
Domestic Dial-In Number: 1-866-393-1607
International Dial-In Number: 1-914-495-8556
Conference ID Number: 1942769

A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-855-859-2056 or 1-404-537-3406, and reference conference ID 1942769.

About Arbutus

Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.

Contact Information

Investors
Mark Murray
President and CEO
Phone: 604-419-3200
Email: ir@arbutusbio.com

Media
Pam Murphy
Investor Relations Consultant
Phone: 604-419-3200
Email: ir@arbutusbio.com

Arbutus Biopharma Logo

 

Source: Arbutus Biopharma Corporation